Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Earlier intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome.
Int Immunopharmacol
December 2024
Hematology & Oncology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu, China; Pediatric Intensive Care Unit, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu, China. Electronic address:
Chimeric antigen receptor T cell (CAR-T) therapy is effective in treating relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the side effects of immune effector cell-associated neurotoxicity syndrome (ICANS) remain a problem. The current frontline therapies for ICANS include steroids and supportive care.
View Article and Find Full Text PDFCase report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.
Front Immunol
May 2024
Laboratory of Molecular Diagnostics and Biotechnology, Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus, Minsk, Belarus.
Article Synopsis
- * A case study highlights the successful use of intrathecal chemotherapy (methotrexate, cytarabine, and dexamethasone) as the first-line treatment for a patient with stage IV Primary mediastinal B-cell lymphoma dealing with grade IV CAR-T cell-associated ICANS.
- * The treatment led to a quick resolution of ICANS, allowing the cessation of systemic corticosteroids and maintaining CAR-T cell function, resulting in the patient being disease-free for 9 months post-therapy.
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis.
Med
June 2024
Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. Electronic address:
Background: Progressive multiple sclerosis (MS) is characterized by compartmentalized smoldering neuroinflammation caused by the proliferation of immune cells residing in the central nervous system (CNS), including B cells. Although inflammatory activity can be prevented by immunomodulatory therapies during early disease, such therapies typically fail to halt disease progression. CD19 chimeric antigen receptor (CAR)-T cell therapies have revolutionized the field of hematologic malignancies.
View Article and Find Full Text PDFIntrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
Nat Med
May 2024
Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). The study's primary endpoints were safety and determination of the maximum tolerated dose.
View Article and Find Full Text PDFLenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy.
Acta Haematol
September 2024
Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Introduction: Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T (CAR-T) cell are effective treatments for acute lymphoblastic leukemia (ALL). Various forms of intra- and extramedullary relapses have been reported after HSCT and CAR-T-cell therapy for ALL; however, no reports have investigated isolated central nervous system (CNS) relapse after HSCT and CAR-T-cell therapy. Hence, no clinical treatment has been established for such rare patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!